Phase 1 Study of ALZT-OP1 Combination Therapy in Normal Healthy Volunteers
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This is an open-labeled, cross-over design, pharmacokinetic study, to determine the
pharmacokinetics of ALZT-OP1 (a combination drug therapy) designated as ALZT-OP1a and
ALZT-OP1b, in both plasma and CSF, following co-administration of the active compounds, in
healthy volunteers, aged 55-75, and in good general health.
Phase:
Phase 1
Details
Lead Sponsor:
AZTherapies, Inc.
Collaborators:
KCAS Panax Clinical Research Pharma Consulting Group AB